Transmission of multidrug-resistant tuberculosis in the USA: A cross-sectional study

The Lancet Infectious Diseases

Volumn 13, Issue 9, 2013, Pages 777-784

  Moonan, Patrick K ^a   Teeter, Larry D ^b   Salcedo, Katya ^c   Ghosh, Smita ^a   Ahuja, Shama D ^d   Flood, Jennifer ^c   Graviss, Edward A ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; CHILD; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; GENOTYPE; HUMAN; INFANT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; MEDICAL RECORDS; MIDDLE AGED; MINISATELLITE REPEATS; MYCOBACTERIUM TUBERCULOSIS; QUESTIONNAIRES; RECURRENCE; TIME FACTORS; TRAVEL; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES; YOUNG ADULT;

EID: 84882581160     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70128-2     Document Type: Article

References (41)

1. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, 13:529-539.
2. Dheda K, Migliori GB The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 2012, 379:773-775.
3. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012, 205(suppl 2):S228-S240.
4. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
5. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
6. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2011 global report on surveillance 2012, WHO, World Health Organization, Geneva.
7. Caminero JA Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010, 14:382-390.
8. Barry PM, Gardner TJ, Funk E, et al. Multistate outbreak of MDR-TB identified by genotype cluster investigation. Emerg Infect Dis 2012, 18:113-116.
9. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011, 377:147-152.
10. Brostrom R, Fred D, Heetderks A, et al. Islands of hope: building local capacity to manage an outbreak of multidrug-resistant tuberculosis in the Pacific. Am J Public Health 2011, 101:14-18.
11. Dara M, de Colombani P, Petrova-Benedict R, et al. Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J 2012, 40:1081-1090.
12. Fenner L, Gagneux S, Helbling P, et al. Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol 2012, 50:388-395.
13. Liu Y, Weinberg MS, Ortega LS, et al. Overseas screening for tuberculosis in US-bound immigrants and refugees. N Engl J Med 2009, 360:2406-2415.
14. Metcalfe JZ, Kim EY, Lin SY, et al. Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007. Emerg Infect Dis 2010, 16:1403-1409.
15. Fitzpatrick C, Floyd K A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012, 30:81.
16. Ghebremichael S, Groenheit R, Pennhag A, et al. Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden. PLoS One 2010, 5:e10893.
17. Munsiff SS, Bassoff T, Nivin B, et al. Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997. Emerg Infect Dis 2002, 8:1230-1238.
18. Nitta AT, Knowles LS, Kim J, et al. Limited transmission of multidrug-resistant tuberculosis despite a high proportion of infectious cases in Los Angeles County, California. Am J Respir Crit Care Med 2002, 165:812-817.
19. Katz D, Albalak R, Wing JS, et al. Setting the agenda: a new model for collaborative tuberculosis epidemiologic research. Tuberculosis (Edinb) 2007, 87:1-6.
20. Ghosh S, Moonan PK, Cowan L, Grant J, Kammerer S, Navin TR Tuberculosis genotyping information management system: enhancing tuberculosis surveillance in the United States. Infect Genet Evol 2012, 12:782-788.
21. Cowan LS, Hooks DP, Christianson S, et al. Evaluation of mycobacterial interspersed repetitive-unit-variable-number tandem-repeat genotyping as performed in laboratories in Canada, France, and the United States. J Clin Microbiol 2012, 50:1830-1831.
22. Moonan PK, Ghosh S, Oeltmann JE, Kammerer JS, Cowan LS, Navin TR Using genotyping and geospatial scanning to estimate Mycobacterium tuberculosis transmission, United States. Emerg Infect Dis 2012, 18:458-465.
23. Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005-2009. PLoS One 2011, 6:e27405.
24. Guidelines for the investigation of contacts of persons with infectious tuberculosis-recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005, 54:1-47. National Tuberculosis Controllers Association, Centers for Disease Control and PreventionCenters for Disease Control and Prevention.
25. Weis S Contact investigations: how do they need to be designed for the 21st century?. Am J Respir Crit Care Med 2002, 166:1016-1017.
26. Click ES, Moonan PK, Winston CA, Cowan LS, Oeltmann JE Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 2012, 54:211-219.
27. Miramontes R, Lambert L, Haddad MB, et al. Public health response to a multidrug-resistant tuberculosis outbreak among Guatemalans in Tennessee, 2007. South Med J 2010, 103:882-886.
28. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011, 6:e17601.
29. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug resistant tuberculosis. JAMA 1996, 276:1229-1235.
30. Fenner L, Gagneux S, Helbling P, et al. Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol 2012, 50:388-395.
31. Lindquist S, Allen S, Field K, et al. Prioritizing tuberculosis genotype clusters for public health action, Washington, USA. Emerg Infect Dis 2013, 19:493-496.
32. CDC immigration requirements: technical instructions for tuberculosis screening and treatment, using cultures and directly observed therapy 2009, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA.
33. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S247. American Thoracic Society, Centers for Disease Control and PreventionCenters for Disease Control and Prevention.
34. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011, 365:2155-2166.
35. Horn DL, Hewlett D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994, 330:1241.
36. Langendam MW, Tiemersma EW, van der Werf MJ, Sandgren A Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review. PLoS One 2013, 8:e53599.
37. Fraser A, Paul M, Attamna A, Leibovici L Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006, 10:19-23.
38. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
39. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
40. Grosset JH, Singer TG, Bishai WR New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012, 16:1005-1014.
41. Horsburgh CR, Haxaire-Theeuwes M, Lienhardt C, et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013, 17:146-152.